Promoting informed decision making about prostate cancer screening

Comprehensive Therapy

Volumn 27, Issue 3, 2001, Pages 195-201

  Chan, E C Y ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER MORTALITY; CANCER SCREENING; DECISION MAKING; INFORMED CONSENT; MEDICAL DECISION MAKING; MEDICAL ETHICS; PATIENT EDUCATION; PROSTATE CANCER;

EID: 0034854290     PISSN: 00988243     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12019-001-0014-4     Document Type: Article

References (82)

1. Cancer statistics, 2000
2. Prostate-specific antigen (PSA) best practice policy
3. Early detection of prostate cancer: I. Prior probability and effectiveness of tests
4. Screening for prostate cancer with prostate-specific antigen: An examination of the evidence
5. American Cancer Society guideline for the early detection of prostate cancer: Update 1997
6. Physician data query [computer database]
7. Clinical guideline: Part III. Screening for prostate cancer
8. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination: Enhancement of specificity with free PSA measurement
9. Prostate-specific antigen: Current status
10. Influence of patient age on the serum PSA concentration: An important clinical observation
11. Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease
12. Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates
13. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota
14. Cancer surveillance series: Interpreting trends in prostate cancer, Part I. Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates
15. Prostate cancer screening: A note of caution
16. The role of prostate-specific antigen (PSA) testing in the recent prostate cancer incidence decline in the United States
17. Cancer surveillance series: Interpreting trends in prostate cancer - Part II: Cause of death misclassification and the recent rise and fall in prostate cancer mortality
18. Prostate cancer screening: What we know and what we need to know
19. Prostate cancer screening in the prostate, lung, colorectal, and ovarian cancer screening trial of the National Cancer Institute
20. The National Cancer Institute multi-screening trial
21. The European screening study for prostate cancer
22. The European randomized study of screening for prostate cancer (ERSPC): An update
23. Early detection of prostate cancer. II. Estimating the risks, benefits, and costs
24. Screening for prostate cancer. A decision analytic view
25. Serum PSA after anatomic radical prostatectomy: The John Hopkins experience after 10 years
26. Using prostate-specific antigen to diagnose prostate cancer: Sailing in uncharted waters
27. Decrease in prostate cancer mortality following introduction of prostate specific antigen (PSA) screening in the federal state of Tyrol, Austria
28. Screening decreases prostate cancer death: First analysis of the 1988 Quebec prospective randomized controlled trial
29. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer
30. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening
31. The Swedish prostate cancer paradox
32. Adherence by African American men to prostate cancer education and early detection
33. Screening for lung cancer
34. Controversies in prostate cancer screening. Analogies to the early lung cancer screening debate
35. Prostate cancer: Are we screening and treating too much?
36. Prostate cancer screening: A place for informed consent?
37. The mammography and prostate-specific antigen controversies: Implication for patient-physician encounters and public policy
38. Prostate cancer screening: What family physicians believe is best
39. Screening for prostate cancer: A comparison of urologists and primary care physicians
40. Use of prostate-specific antigen for prostate cancer screening in primary care practice
41. Prostate-specific antigen testing practices and outcomes
42. Informed consent for PSA screening: Does it happen?
43. Screening for prostate cancer with the prostate-specific antigen test. Are patients making informed decisions?
44. Screening by the prostate-specific antigen test: What do the patients know?
45. Public awareness of prostate cancer and the prostate-specific antigen test
46. Knowledge, beliefs, and prior screening behavior among blacks and whites reporting for prostate cancer screening
47. Differences between African American and Caucasian men participating in a community-based prostate cancer screening program
48. African-American males and prostate cancer: Assessing knowledge levels in the community
49. Cancer Statistics, 1999
50. Prostate cancer and African American men
51. Stage at presentation and survival of white and black patients with prostate carcinoma
52. Prostate cancer in blacks: An update from the American College of Surgeons' patterns of care studies
53. Informed decision making in outpatient practice. Time to get back to basics
54. Involving patients in medical decisions. How can physicians do better?
55. Informed consent and prostate specific antigen screening: What patients ought to know
56. Informed consent in theory and practice: Legal and medical perspectives on the informed consent doctrine and a proposed reconceptualization
57. Changes in the concept of informed consent in medical encounters
58. How and when should physicians discuss clinical decisions with patients?
59. Two models of implementing informed consent
60. Legal and ethical myths about informed consent
61. Genetic testing for susceptibility to adult-onset cancer. The process and content of informed consent
62. Preferences of husbands and wives for prostate cancer screening
63. Four models of the physician-patient relationship
64. Physician recommendations and patient autonomy: Finding a balance between physician power and patient choice
65. Science, ethics and the making of clinical decisions. Implications for risk factor intervention
66. What should men know about prostate-specific antigen screening before giving informed consent?
67. Strategies to overcome barriers to early detection of cancer among older adults
68. Public awareness of screening programs
69. Perils, pitfalls, and possibilities in talking about medical risk
70. The potential benefits of decision aids in clinical medicine
71. Treating people with information: An analysis and review of approaches to communicating health risk information
72. Decision aids for patients considering options affecting cancer outcomes: Evidence of efficacy and policy implications
73. A patient decision aid regarding antithrombotic therapy for stroke prevention in atrial fibrillation. A randomized controlled trial
74. The importance of patient preference in the decision to screen for prostate cancer
75. A randomized controlled trial of shared decision making for prostate cancer screening
76. The impact of informed consent on patient interest in prostate-specific antigen screening